Compare Amgen, Inc. (AMGN) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Otis Worldwide Corp — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Otis Worldwide Corp trades at $73.33 (market cap $28.05B). The key difference: Amgen, Inc. is far larger — about 7× Otis Worldwide Corp's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | OTIS | |
|---|---|---|
Market Cap | $196.12B | $28.05B |
Sector | Health | Industrials |
52-Week High | $388.16 | $101.07 |
52-Week Low | $271.18 | $69.34 |
Enterprise Value | $241.41B | $35.43B |
Dividend Yield | 2.77% | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Otis Worldwide trades at $73.09, up 1.51% today, amid a bearish technical signal despite neutral oscillators. The company reported mixed quarterly earnings, with Q1 2026 missing estimates, but maintains steady revenue growth and a 10.11% net income margin. Recent news highlights strategic modernization projects and a 5% dividend increase, while analyst consensus remains cautiously optimistic with a $94 price target.
The stock presents a value opportunity with a P/E of 19.44 below historical averages, but faces headwinds from China exposure and margin pressure. Upside potential exists if earnings rebound, though high debt and competitive risks warrant caution for investors seeking stable industrial exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
